Comparison of single-dose oral grepafloxacin with cefixime for treatment of uncomplicated gonorrhea in men. The STD Study Group.

1997 ◽  
Vol 41 (8) ◽  
pp. 1843-1845 ◽  
Author(s):  
E W Hook ◽  
W M McCormack ◽  
D Martin ◽  
R B Jones ◽  
K Bean ◽  
...  
Keyword(s):  
Single Dose ◽  
Neisseria Gonorrhoeae ◽  
Open Study ◽  
Study Group ◽  
Dose Oral ◽  
Male Patients ◽  
Resistant Strains ◽  
Oral Doses ◽  
Uncomplicated Gonorrhea

In a randomized open study, 351 male patients with uncomplicated gonorrhea were given single oral doses of grepafloxacin (400 mg) or cefixime (400 mg). In the 299 microbiologically evaluable patients, urethral infections were cured in 99% (147 of 149) of those receiving grepafloxacin and 97% (145 of 150) of those given cefixime. Eradication rates for both regimens were 100% in the 16% (47 of 299) of participants who were infected with penicillin-resistant Neisseria gonorrhoeae and 97% in the 21% (62 of 299) of participants infected with tetracycline-resistant strains. Grepafloxacin is a well-tolerated alternative to cefixime for treatment of uncomplicated gonorrhea in males.

scholarly journals Comparison of single-dose cefuroxime axetil with ciprofloxacin in treatment of uncomplicated gonorrhea caused by penicillinase-producing and non-penicillinase-producing Neisseria gonorrhoeae strains.

1996 ◽  
Vol 40 (12) ◽  
pp. 2775-2780 ◽  
Author(s):  
E M Thorpe ◽  
J R Schwebke ◽  
E W Hook ◽  
A Rompalo ◽  
W M McCormack ◽  
...  
Keyword(s):  
Single Dose ◽  
Oral Dose ◽  
Confidence Interval ◽  
Neisseria Gonorrhoeae ◽  
Single Oral Dose ◽  
Cefuroxime Axetil ◽  
Female Patients ◽  
Male Patients ◽  
Males And Females ◽  
Uncomplicated Gonorrhea

A randomized, multicenter, investigator-blind trial was conducted to compare the efficacies of cefuroxime axetil and ciprofloxacin for treatment of patients with uncomplicated gonorrhea caused by penicillinase-producing Neisseria gonorrhoeae (PPNG). A total of 832 patients (434 females and 398 males) received a single oral dose of cefuroxime axetil (1,000 mg [417 patients]) or ciprofloxacin (500 mg [415 patients]). N. gonorrhoeae was eradicated from the cervix in 114 of 118 (97%) and 118 of 119 (99%) bacteriologically evaluable females treated with cefuroxime axetil and ciprofloxacin, respectively (P = 0.213; difference, -2%; 95% confidence interval, -6 to 1%), and from the urethra in 154 of 166 (93%) and 171 of 171 (100%) bacteriologically evaluable male patients treated with cefuroxime axetil and ciprofloxacin, respectively (P < 0.001; difference, -7%; 95% confidence interval, -11 to -3%). Both treatments were effective in eradicating N. gonorrhoeae in females with rectal infections (cefuroxime axetil, 29 of 30 [97%]; ciprofloxacin, 25 of 25 [100%]; P = 1.00). In small numbers of patients, cefuroxime axetil was less effective than ciprofloxacin in treating males with pharyngeal infections (eradication in 4 of 10 and in 8 of 8 patients, respectively; P = 0.013). PPNG was eradicated from the cervix in 22 of 23 (96%) and 32 of 32 (100%) bacteriologically evaluable female patients treated with cefuroxime axetil and ciprofloxacin, respectively (P = 0.418; difference, -4%; 95% confidence interval, -13 to 4%), and from the urethra in 35 of 36 (97%) and 34 of 34 (100%) bacteriologically evaluable male patients treated with cefuroxime axetil and ciprofloxacin, respectively (P = 1.00; difference, -3%; 95% confidence interval, -8 to 3%). The incidences of drug-related adverse events were similar for the two study drugs. In summary, treatment with a single oral dose of cefuroxime axetil is as effective as treatment with a single oral dose of ciprofloxacin in eradicating PPNG from males and females with uncomplicated gonorrhea (urethral and endocervical), and both regimens are well-tolerated. However, in the present study, cefuroxime axetil was less effective than ciprofloxacin in treating urethral gonococcal infections in male patients, although both study drugs were highly effective in treating cervical gonococcal infections in female patients.

Single-Dose Therapy of Anogenital and Pharyngeal Gonorrhoea with Ciprofloxacin

1992 ◽  
Vol 3 (1) ◽  
pp. 49-51 ◽  
Author(s):  
T Balachandran ◽  
A P Roberts ◽  
B A Evans ◽  
B S Azadian
Keyword(s):  
Adverse Reaction ◽  
Single Dose ◽  
Oral Dose ◽  
Neisseria Gonorrhoeae ◽  
Treatment Failure ◽  
Single Oral Dose ◽  
Open Study ◽  
Dose Therapy ◽  
Single Dose Therapy

A single dose of ciprofloxacin, 250 mg by mouth, was used in an open study to treat pharyngeal or rectal gonorrhoea or both in 64 patients (32 men and 32 women). The study also included 151 men with urethral gonorrhoea and 53 women with cervical or urethral gonorrhoea. Ciprofloxacin cured 63 (98%) patients with pharyngeal or rectal gonorrhoea (including 5 patients with penicillinase-producing Neisseria gonorrhoeae; PPNG), 147 (97%) men with urethral gonorrhoea (including 8 with PPNG) and 52 (98%) women with cervical or urethral gonorrhoea. All the isolates of N. gonorrhoeae were sensitive to 0.03 mg/l of ciprofloxacin. Five of the 6 patients with treatment failure were subsequently cured by a single oral dose of ciprofloxacin 250 mg. None of the patients reported an adverse reaction. Ciprofloxacin 250 mg as a single oral dose is effective and safe in treating patients with pharyngeal or rectal gonorrhoea, including those with PPNG strains.

scholarly journals Dose-ranging study of CP-99,219 (trovafloxacin) for treatment of uncomplicated gonorrhea.

1996 ◽  
Vol 40 (7) ◽  
pp. 1720-1721 ◽  
Author(s):  
E W Hook ◽  
G B Pinson ◽  
C J Blalock ◽  
R B Johnson
Keyword(s):  
Neisseria Gonorrhoeae ◽  
Dose Ranging ◽  
Oral Doses ◽  
To Receive ◽  
Uncomplicated Gonorrhea

Thirty-nine patients with uncomplicated gonorrhea were randomized to receive single, oral 50-, 100-, or 200-mg doses of trovafloxacin (CP-99,219), a new quinolone antibiotic. All 31 evaluable patients were cured of infection. Trovafloxacin was well tolerated. The trovafloxacin MICs at which 50 and 90% of 36 Neisseria gonorrhoeae isolates are inhibited were 0.002 and 0.004 mg/liter, respectively (MIC range, < 0.0005 to 0.008 mg/liter). These preliminary studies suggest that trovafloxacin is effective for the treatment of uncomplicated gonorrhea at single oral doses as low as 50 mg.

The Treatment of Non-Gonococcal Urethritis with Single Dose Oral Azithromycin

1995 ◽  
Vol 23 (5) ◽  
pp. 386-393 ◽  
Author(s):  
T Erdog#x0342;ru ◽  
A Ag#x0342;açfidan ◽  
M Önel ◽  
S Badur ◽  
Ö Ang#x0342; ◽  
...  
Keyword(s):  
Single Dose ◽  
Ureaplasma Urealyticum ◽  
Microbiological Diagnosis ◽  
Dose Administration ◽  
Complete Eradication ◽  
Gonococcal Urethritis ◽  
Dose Oral ◽  
Male Patients ◽  
Oral Azithromycin

In an uncontrolled study, the efficacy of azithromycin in the treatment of non-gonococcal urethritis was assessed in 41 male patients aged between 20 and 40 years with a mean age of 27 ± 5 years. Clinical and microbiological diagnosis confirmed that 28 men were found positive for Chlamydia trachomatis, 10 for Ureaplasma urealyticum and three for both C. trachomatis and U. urealyticum. All patients received 1 g azithromcyin orally (four 250 mg capsules). The length of time between the treatment and following visits were 7 – 10 days and 14 – 21 days for second and third visits, respectively. Complete eradication was achieved in 27 out of 41 patients. Of the remaining 14, six were found positive for C. trachomatis and were excluded as they did not return for the follow-up visit, one patient did not achieve complete eradication, one patient infected with both C. trachomatis and U. urealyticum failed to achieve complete eradication, and six patients infected with U. urealyticum failed to be completely cured. No adverse effects were reported in any patient. Single dose administration of 1 g azithromycin appears to be an effective and well-tolerated treatment for chlamydial urethritis and an advantage in terms of patient compliance.

scholarly journals Efficacy and Safety of Single-Dose Oral Delafloxacin Compared With Intramuscular Ceftriaxone for Uncomplicated Gonorrhea Treatment

2019 ◽  
Vol 46 (5) ◽  
pp. 279-286 ◽  
Author(s):  
Edward W. Hook ◽  
Matthew R. Golden ◽  
Stephanie N. Taylor ◽  
Eugenia Henry ◽  
Carol Tseng ◽  
...  
Keyword(s):  
Single Dose ◽  
Efficacy And Safety ◽  
Dose Oral ◽  
Uncomplicated Gonorrhea

scholarly journals Grepafloxacin Versus Cefixime as Single-Dose Therapy for Uncomplicated Gonorrhea in Women

1997 ◽  
Vol 5 (6) ◽  
pp. 370-375 ◽  
Author(s):  
T. F. Mroczkowski ◽  
E. W. Hook III ◽  
R. B. Jones ◽  
W. M. McCormack ◽  
D. H. Martin
Keyword(s):  
Single Dose ◽  
Transmitted Disease ◽  
The United States ◽  
Response To Therapy ◽  
Sexually Transmitted ◽  
Treatment Groups ◽  
Cure Rates ◽  
Study Participants ◽  
Oral Doses ◽  
Uncomplicated Gonorrhea

Objective:To compare the efficacy and tolerance of single-dose grepafloxacin with cefixime for treatment of uncomplicated gonorrhea in women.Methods:Women attending nine sexually-transmitted-disease clinics in the United States who had suspected uncomplicated gonorrhea were enrolled in an open study. Participants were randomized to receive single oral doses of grepafloxacin (400 mg) or cefixime (400 mg), and efficacy was evaluated in those who returned for follow-up assessment 5 to 10 days later. The primary measure of efficacy was microbiological response to therapy as determined by pre- and posttreatment culture results forNeisseria gonorrhoeae.Results:Of 380 patients enrolled, 124 in the grepafloxacin group and 131 in the cefixime group were evaluated for microbiological response. Cervical gonococcal infections were eradicated in 99% of patients in both treatment groups, with only one persistent infection in each group. All pharyngeal (n = 15) and rectal (n = 32) gonococcal infections treated with grepafloxacin were cured, whereas 5 of 16 (31%) pharyngeal and 1 of 38 (3%) rectal infections failed to respond to cefixime. Although a third (123 of 386) ofN. gonorrhoeaepretreatment isolates were resistant to penicillin or tetracycline, this had no impact on cure rates. Both drugs were well tolerated, with vaginitis being the most common treatment-related adverse event in each group.Conclusions:This study shows that single-dose grepafloxacin is at least as effective as cefixime for treating women with uncomplicated cervical gonorrhea. Grepafloxacin also appears to be highly effective against extragenital infections.

scholarly journals A Phase 2 Trial of Oral Solithromycin 1200 mg or 1000 mg as Single-Dose Oral Therapy for Uncomplicated Gonorrhea

2015 ◽  
Vol 61 (7) ◽  
pp. 1043-1048 ◽  
Author(s):  
Edward W. Hook ◽  
Matthew Golden ◽  
Brian D. Jamieson ◽  
Paula B. Dixon ◽  
Hanne S. Harbison ◽  
...  
Keyword(s):  
Single Dose ◽  
Oral Therapy ◽  
Phase 2 ◽  
Phase 2 Trial ◽  
Dose Oral ◽  
Uncomplicated Gonorrhea

Clinical Evaluation of Single-Dose Oral Bacampicillin or Ampicillin in Therapy of Uncomplicated Gonorrhea

1981 ◽  
Vol 3 (1) ◽  
pp. 166-169 ◽  
Author(s):  
K. F. Wagner ◽  
G. Counts ◽  
K. K. Holmes ◽  
P. F. Sparling ◽  
L. O. Gentry ◽  
...  
Keyword(s):  
Single Dose ◽  
Clinical Evaluation ◽  
Dose Oral ◽  
Uncomplicated Gonorrhea

scholarly journals Successful Treatment of Uncomplicated Gonococcal Urethritis in HIV-Infected Patients with Single-Dose Oral Cefpodoxime

2010 ◽  
Vol 21 (3) ◽  
pp. e109-e110
Author(s):  
George Psevdos ◽  
Victoria Sharp
Keyword(s):  
United States ◽  
Single Dose ◽  
Neisseria Gonorrhoeae ◽  
Disease Control ◽  
Successful Treatment ◽  
The United States ◽  
Homosexual Men ◽  
Limited Data ◽  
Control And Prevention ◽  
Dose Oral

Fluoroquinolones are no longer recommended for the treatment of gonococcal infections in the United States. Cephalosporins – ceftriaxone and cefixime – are the treatment of choice, as suggested by the Centers for Disease Control and Prevention (USA). There are limited data on the efficacy of cefpodoxime for the treatment of uncomplicated gonococcal infections. Two cases of HIV-infected homosexual men who were successfully treated with cefpodoxime for urethritis caused byNeisseria gonorrhoeaeare described in the present study.

Sign in / Sign up

Export Citation Format

Share Document